UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Core Viewpoint - UroGen Pharma Ltd. is set to report its third quarter 2025 financial results on November 6, 2025, followed by a live audio webcast and conference call, indicating ongoing transparency and engagement with investors [1][2]. Company Overview - UroGen Pharma Ltd. is a biotech company focused on developing innovative treatments for urothelial and specialty cancers, emphasizing the need for better patient options [3]. - The company has developed RTGel®, a proprietary sustained-release hydrogel technology aimed at enhancing the therapeutic profiles of existing drugs, allowing for prolonged exposure of urinary tract tissue to medications [3]. - UroGen's first product is approved for treating low-grade upper tract urothelial cancer, while its second product is the first FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, both designed for non-surgical tumor ablation [3].